Joris van den Hurk studied biomedical sciences at the leiden university medical center. During his master he investigated a new mouse model for Duchenne muscular dystrophy at the LUMC and the development of C. elegans gonads in Toronto. In November 2021 he joined the DCVA Double Dose consortium as a PhD student under the supervision of Dr. Daan Westenbrink, Dr. Herman Sillje and Prof. Dr. Rudolf de Boer. His current project focusses on mitochondrial and metabolic function and dysfunction in cardiomyocytes of PLN mice. The goal is to find and test new therapeutic targets for genetic dilated cardiomyopathies.
Investigating and treating phospholamban cardiomyopathy
MITOchondrial therapy to increase cardiac FORCE and enhance exercise performance